M
María Montoro
Researcher at Pfizer
Publications - 37
Citations - 597
María Montoro is an academic researcher from Pfizer. The author has contributed to research in topics: Psoriatic arthritis & Rheumatoid arthritis. The author has an hindex of 12, co-authored 35 publications receiving 509 citations. Previous affiliations of María Montoro include Hospital General Universitario Gregorio Marañón.
Papers
More filters
Journal ArticleDOI
Predictive value of Doppler ultrasound-detected synovitis in relation to failed tapering of biologic therapy in patients with rheumatoid arthritis
Esperanza Naredo,Lara Valor,Inmaculada de la Torre,María Montoro,N. Bello,Julia Martínez-Barrio,Lina Martínez-Estupiñán,Juan Carlos Nieto,J.G. Ovalles-Bonilla,Diana Hernández-Flórez,Carlos M. González,Francisco Javier López-Longo,Indalecio Monteagudo,Luis Carreño +13 more
TL;DR: The results suggest that the presence of Doppler-detected synovitis may predict BT tapering failure in RA patients in sustained clinical remission.
Journal ArticleDOI
Ultrasound joint inflammation in rheumatoid arthritis in clinical remission: how many and which joints should be assessed?
Esperanza Naredo,Lara Valor,Inmaculada de la Torre,Julia Martínez-Barrio,M. Hinojosa,Francisco Aramburu,J.G. Ovalles-Bonilla,Diana Hernández,María Montoro,Carlos M. González,Javier López-Longo,Indalecio Monteagudo,Luis Carreño +12 more
TL;DR: To investigate the sensitivity for detecting subclinical synovitis of different reduced joint ultrasound (US) assessment models as compared with a comprehensive US assessment in rheumatoid arthritis patients in clinical remission, a large number of patients were diagnosed with RA.
Journal ArticleDOI
Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0
Juan J. Gomez-Reino,Carlos Rodríguez-Lozano,Cristina Campos-Fernandez,María Montoro,Miguel Ángel Descalzo,Loreto Carmona +5 more
TL;DR: In RA, the discontinuation rate of TNF antagonists in the first year of treatment is higher more recently than a decade ago, inefficacy being the main reason for the increased rate.
Journal ArticleDOI
Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study
TL;DR: Nearly 60% of Spanish PsA patients achieve MDA in routine clinical practice, and MDA remains one of the most useful therapeutic targets for PsA since patients who reached this state also had a significantly lower impact of disease according to PsAID.
Journal ArticleDOI
Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study.
Alejandro Balsa,Raimon Sanmartí,José Rosas,Victor Martin,Ana Cabez,Susana Gómez,María Montoro +6 more
TL;DR: In patients with RA or SpA and secondary failure, the development of ADA against ADL or INF, but not ETN, appears to be one of the main reasons for secondary treatment failure,but not the only one.